Is GLOW approved as a medicine, and where?

The regulatory review of GLOW is incomplete. See the article's sources for product- and country-specific findings and remaining uncertainties. Review status means neither worldwide approval nor worldwide absence of approval.

What is GLOW studied for?

Research has examined Component-level tissue-repair and cosmetic research (see linked monographs). Being studied for an area does not mean it is proven or approved for it.

Does GLOW have human clinical trials?

The evidence review of GLOW is in progress. The article's study appraisal identifies any human studies located and their limitations. An ongoing review does not itself mean that human studies are absent.

Index by category›

Peptide Blends

GLOW

Name: GLOW
Creator: PeptideInfo Wiki editorial collective
Published: 2026-10-07

GLOW blend; GLOW peptide; GLOW 70

3 min read · Updated October 7, 2026 · 10 references

Curated by PeptideInfo Wikilast reviewed October 7, 2026how we verify

In brief · TL;DR

Source record — verification pending

GLOW is a vendor blend name (usually GHK-Cu + BPC-157 + TB-500), not a single drug substance. There is no controlled combination data. Component pages carry the actual evidence. Not an approved medicine; no blend dose is established.

Evidence: Catalog coverage only; independent identity, evidence and regulatory review is still pending.

Trade blend / co-lyophilisate — not a new molecule and not a pharmacopoeial standard
Typical labelled ratio in vendor listings is ~50 mg GHK-Cu + ~10 mg BPC-157 + ~10 mg TB-500 (~70 mg total); ratios vary and are not clinical doses
No RCT or controlled animal study of the fixed three-peptide combination was identified (2026-10-07 dossier)
TB-500 in a vial is often the Ac-LKKTETQ fragment — not full-length thymosin β4; lot COAs sometimes conflate the two
See component monographs for evidence; do not infer blend synergy from component literature

↓ Read the full referenced entry below

GLOW is a commercial name for a lyophilized three-peptide mixture typically labelled as GHK-Cu plus BPC-157 plus TB-500 — not a new covalent molecule. No controlled study of the combination was identified; any evidence is component-wise only.

Body & signals →

No receptor relationship mapped here yet. This does not mean the molecule has no biological effects.

Review pending

Contents7

Editorial review pending — noindex

This page remains under independent editorial review (reviewPending). It is visible in the wiki but noindexed. Editorial lane: scope-review-blend.

No controlled combination data

In the reviewed 2026-10-07 dossier, no controlled study of GHK-Cu + BPC-157 + TB-500 as a fixed blend was identified. Claims of synergy, a blend "protocol", or a clinical stack dose lack primary literature support. Evidence, where it exists, is component-wise only.

Section 1 of 7What "GLOW" means

What "GLOW" means

GLOW is a catalog / brand name used by multiple research vendors for a physical mixture (often co-lyophilized) of three peptides. It is not a covalent conjugate, has no CAS/PubChem CID of its own, and is not an FDA/EMA-approved product.

A commonly repeated label pattern ("GLOW 70") is approximately:

Component	Typical labelled amount	Existing monograph
GHK-Cu	~50 mg	Mixed / disputed (topical cosmetic human data; injectable research-only)
BPC-157	~10 mg	Preclinical — animal/in-vitro only
TB-500	~10 mg	Preclinical — fragment vs full Tβ4 caveat

Label milligrams are not established clinical doses. Other ratios (e.g. "GLOW 50") appear; batch COAs can disagree with the label.

Related catalog stub: The Wolverine Blend (BPC-157 + TB-500 without GHK-Cu) — also review-pending. "GLOW ≈ Wolverine + GHK-Cu" is vendor jargon, not a scientific taxonomy.

Section 2 of 7TB-500 ≠ full-length thymosin β4

TB-500 ≠ full-length thymosin β4

PeptideInfo already separates:

TB-500 — typically the Ac-LKKTETQ actin-binding fragment (~889 Da)
Thymosin beta-4 — full-length 43-aa protein (~4963 Da)

Vendor pages and COAs sometimes mix CAS 77591-33-4 (full Tβ4) with fragment masses. Identity of the "TB-500" line in any GLOW vial is lot-specific.

Section 3 of 7Component evidence (pointer only)

Component evidence (pointer only)

Component	What the component literature supports (high level)	What it does not support
GHK-Cu	Topical cosmetic use with some human skin studies; CIR/safety review context	Established systemic injectable efficacy for a "research peptide" use
BPC-157	Extensive rodent/in-vitro repair and angiogenesis literature	Published human efficacy; salt-form specifics for every bottle
TB-500	Analytical ID of the marketed fragment; biology largely from full Tβ4 models	Human trials of the fragment itself

PubMed queries on "GLOW blend" / the three-way combination did not yield relevant controlled blend studies after filtering false positives on the everyday word "glow".

Section 4 of 7Claims vs evidence

Claims vs evidence

Claim	Assessment
GLOW = GHK-Cu + BPC-157 + TB-500	Partially supported as a trade definition — confirm ratio on COA
"Synergistic tissue repair"	Not verified for the blend
Fixed clinical injection schedule	Reject — no established human blend dose
One CAS number for GLOW	False — it is a mixture
Same evidence level as approved drugs	False
TB-500 in the blend = full Tβ4	Often wrong / unclear — needs lot ID

Section 5 of 7Regulatory note

Regulatory note

No approved "GLOW" medicine was identified. PCAC July 2026 discussed several related substances as separate bulk drug substance nominations, not as this blend. This page does not assess compounding legality (legalityNotAssessed: true).

Section 6 of 7Related pages

KLOW — GLOW core plus KPV
GHK-Cu, BPC-157, TB-500, Thymosin beta-4
The Wolverine Blend

Section 7 of 7What this page intentionally omits

What this page intentionally omits

Any reconstitution, injection, or "stack" protocol
Synergy percentages or blend safety grades
Medical use advice

References10

References

1.
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration — Pickart L, Vasquez-Soltero JM, Margolina A, BioMed Research International, 2015. source
2.
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data — Pickart L, Margolina A, International Journal of Molecular Sciences, 2018. source
3.
Effects of Topical Copper Tripeptide Complex on CO2 Laser-Resurfaced Skin — Miller TR, Wagner JD, Baack BR, Eisbach KJ, Archives of Facial Plastic Surgery, 2006. source
4.
Safety Assessment of Tripeptide-1… as Used in Cosmetics — Johnson W Jr, et al., International Journal of Toxicology, 2018. source
5.
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500 — Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P, Drug Testing and Analysis, 2012. source
6.
The actin binding site on thymosin beta4 promotes angiogenesis — Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK, FASEB Journal, 2003. source
7.
PeptideInfo — GHK-Cu source
8.
PeptideInfo — BPC-157 source
9.
PeptideInfo — TB-500 source
10.
PeptideInfo — Thymosin beta-4 source

Frequently asked questions4

Frequently asked questions

What is GLOW?: GLOW is a commercial name for a lyophilized three-peptide mixture typically labelled as GHK-Cu plus BPC-157 plus TB-500 — not a new covalent molecule. No controlled study of the combination was identified; any evidence is component-wise only.
Is GLOW approved as a medicine, and where?: The regulatory review of GLOW is incomplete. See the article's sources for product- and country-specific findings and remaining uncertainties. Review status means neither worldwide approval nor worldwide absence of approval.
What is GLOW studied for?: Research has examined Component-level tissue-repair and cosmetic research (see linked monographs). Being studied for an area does not mean it is proven or approved for it.
Does GLOW have human clinical trials?: The evidence review of GLOW is in progress. The article's study appraisal identifies any human studies located and their limitations. An ongoing review does not itself mean that human studies are absent.

Educational disclaimer. This article summarizes published research for informational purposes and is not medical advice. The editorial review of GLOW is incomplete. Source-supported findings and remaining uncertainties are stated in the article; review status does not certify approval, safety or suitability for use. Consult a qualified healthcare professional before making health decisions.